Quick Takeaways
- ROIV - Roivant Sciences Ltd. has 25 insiders with reported activity on this page.
- Net insider value flow over the last year: -$723,842,018.
- Recent transaction rows are available for direct filing-level review.
- Info
- Significant Ownership
- Insider Ownership
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 25 Insiders of Roivant Sciences Ltd.
- Symbol
- ROIV on Nasdaq
- Location
- London
What Changed
- Buy value: $49,957; sell value: $723,891,974.
- Net share flow: -35,265,379.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$723,842,018.
Buys
$49,957
Shares: 3,315
Insiders: 1
Sells
$723,891,975
Shares: 35,268,694
Insiders: 11
Net
-$723,842,018
Shares: -35,265,379
Insiders: -10
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 7,728,654 | $0 | $207,452,092 | -$207,452,092 |
| 3-6 | 0 | 19,098,670 | $0 | $409,266,727 | -$409,266,727 |
| 6-9 | 3,315 | 4,351,908 | $49,957 | $61,086,800 | -$61,036,843 |
| 9-12 | 0 | 4,089,462 | $0 | $46,086,356 | -$46,086,356 |
Roivant Sciences Ltd. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Dexcel Pharma Technologies Ltd. | 10%+ Owner | $1,064,491,735 | Mixed | 10 Nov 2022 | ||
| Vivek Ramaswamy | 10%+ Owner | $1,012,161,165 | -$160,007,087 | -14% | Mixed | 11 Dec 2025 |
| SVF Investments (UK) Ltd | 10%+ Owner | $755,877,753 | Mixed | 28 Sep 2023 | ||
| Sumitomo Chemical Co., Ltd. | 10%+ Owner | $737,448,709 | Mixed | 22 Jun 2023 | ||
| Mayukh Sukhatme | President & CIO, Director | $405,304,288 | -$38,507,032 | -8.7% | Mixed | 30 Mar 2026 |
| Keith S. Manchester | Director | $400,874,218 | -$98,028,232 | -20% | Filing P/S | 11 Feb 2026 |
| Daniel Allen Gold | Director | $400,874,218 | -$98,028,232 | -20% | Filing P/S | 11 Feb 2026 |
| QVT Financial LP | Director by Deputization | $400,874,218 | -$98,028,232 | -20% | Filing P/S | 11 Feb 2026 |
| Matthew Gline | CEO, Director | $369,461,813 | -$37,673,243 | -9.3% | Mixed | 30 Mar 2026 |
| Frank Torti | President and Vant Chair | $294,610,310 | -$82,039,460 | -22% | Mixed | 31 Mar 2026 |
| Eric Venker | President & Immunovant CEO | $169,393,994 | -$99,286,120 | -37% | Mixed | 17 Mar 2026 |
| VIKING GLOBAL PERFORMANCE LLC | 10%+ Owner | $133,352,577 | Mixed | 22 Jun 2023 | ||
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $133,352,577 | Mixed | 22 Jun 2023 | ||
| Benjamin Zimmer | President, Roivant Health | $12,083,532 | Mixed | 01 Oct 2021 | ||
| Richard Pulik | Cfo | $5,140,013 | -$9,122,307 | -64% | Mixed | 20 Mar 2026 |
| Ilan Oren | Director | $2,744,455 | Mixed | 20 Jan 2026 | ||
| James C. Momtazee | Director | $2,505,509 | Mixed | 20 Jan 2026 | ||
| Jennifer Humes | Chief Accounting Officer | $2,120,719 | Mixed | 20 Mar 2026 | ||
| Rakhi Kumar | Chief Accounting Officer | $1,739,920 | Mixed | 20 Feb 2025 | ||
| Meghan FitzGerald | Director | $1,179,334 | -$1,921,500 | -62% | Filing P/S | 26 Mar 2026 |
| Andrew Lo | Director | $539,670 | Mixed | 15 Sep 2022 | ||
| Melissa B. Epperly | Director | $453,258 | -$1,200,573 | -73% | Filing P/S | 16 Mar 2026 |
| Masayo Tada | Director | Mixed | 01 Oct 2021 | |||
| Hiroshi Nomura | Director | Mixed | 16 Sep 2022 | |||
| Patrick Machado | Director | Mixed | 01 Oct 2021 |
Top shareholders of Roivant Sciences Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
|
Company |
10%
|
73,641,253
|
$1,691,539,587 | +$180,585,293 | 27 Feb 2026 | |
| MORGAN STANLEY |
13F
13D/G
|
Company |
8%
from 13D/G
|
58,359,553
|
$1,266,402,346 | — | 31 Dec 2025 | |
| Dexcel Pharma Technologies Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
102,849,443
|
$1,064,491,735 | — | 10 Nov 2022 | |
| Vivek Ramaswamy |
13D/G
3/4/5
|
Ramaswamy Vivek · 10%+ Owner |
6.8%
|
48,428,792
|
$1,054,779,090 | -$752,013,959 | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.9%
|
42,059,041
|
$912,681,190 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5.8%
|
41,170,475
|
$893,399,288 | — | 31 Dec 2025 | |
| SVF Investments (UK) Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
73,031,667
|
$755,877,753 | — | 28 Sep 2023 | |
| Sumitomo Chemical Co., Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
71,251,083
|
$737,448,709 | — | 22 Jun 2023 | |
| QVT Financial LP |
13F
13D/G
3/4/5
|
Company · Director by Deputization |
4.3%
from 13D/G
|
26,387,021
|
$572,598,356 | — | 31 Dec 2025 | |
| Mayukh Sukhatme |
3/4/5
|
President & CIO, Director |
2.6%
|
18,677,617
|
$405,304,288 | -$38,507,032 | 30 Mar 2026 | |
| Daniel Allen Gold |
3/4/5
|
Director |
—
mixed-class rows
|
15,161,055
mixed-class rows
|
$400,874,218 | -$98,028,232 | 11 Feb 2026 | |
| Keith S. Manchester |
3/4/5
|
Director |
—
mixed-class rows
|
15,161,055
mixed-class rows
|
$400,874,218 | -$98,028,232 | 11 Feb 2026 | |
| UBS Group AG |
13F
|
Company |
2.6%
|
18,390,792
|
$399,080,188 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.4%
|
17,361,465
|
$376,743,791 | — | 31 Dec 2025 | |
| Matthew Gline |
3/4/5
|
CEO, Director |
2.4%
|
17,025,890
|
$369,461,813 | -$37,673,243 | 30 Mar 2026 | |
| SB INVESTMENT ADVISERS (UK) LTD |
13D/G
13F
|
SB Investment Advisers (UK) Limited · Company |
2.3%
|
16,413,603
|
$357,488,273 | -$520,575,193 | 31 Dec 2025 | |
| VIKING GLOBAL INVESTORS LP |
13D/G
3/4/5
13F
|
10%+ Owner · Company |
3.4%
|
23,594,831
|
$356,989,793 | -$161,027,803 | 30 Sep 2025 | |
| Frank Torti |
3/4/5
|
President and Vant Chair |
—
mixed-class rows
|
16,602,696
mixed-class rows
|
$294,610,310 | -$82,039,460 | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.5%
|
10,982,683
|
$238,324,221 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.5%
|
10,677,894
|
$231,710,300 | — | 31 Dec 2025 | |
| Two Seas Capital LP |
13F
|
Company |
1.4%
|
9,791,891
|
$212,484,035 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.3%
|
9,247,468
|
$200,666,214 | — | 31 Dec 2025 | |
| Rubric Capital Management LP |
13F
|
Company |
1.3%
|
9,000,000
|
$195,300,000 | — | 31 Dec 2025 | |
| Patient Square Capital LP |
13F
|
Company |
1.1%
|
8,166,047
|
$177,203,220 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
8,153,546
|
$176,972,083 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.1%
|
7,985,461
|
$173,284,504 | — | 31 Dec 2025 | |
| Eric Venker |
3/4/5
|
President & Immunovant CEO |
—
mixed-class rows
|
6,492,380
mixed-class rows
|
$169,393,994 | -$99,286,120 | 17 Mar 2026 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.97%
|
6,937,112
|
$150,535,330 | — | 31 Dec 2025 | |
| VIKING GLOBAL PERFORMANCE LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
12,884,307
|
$133,352,577 | — | 22 Jun 2023 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.78%
|
5,555,017
|
$120,543,869 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.75%
|
5,335,125
|
$115,773,000 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
0.73%
|
5,195,859
|
$112,750,140 | — | 31 Dec 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.49%
|
3,514,833
|
$76,271,877 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.48%
|
3,458,926
|
$75,058,694 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.48%
|
3,428,962
|
$74,408,475 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.46%
|
3,285,928
|
$71,304,638 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.45%
|
3,239,696
|
$70,301,403 | — | 31 Dec 2025 | |
| BlackBarn Capital Partners LP |
13F
|
Company |
0.43%
|
3,084,300
|
$66,929,310 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.41%
|
2,928,328
|
$63,544,718 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
0.41%
|
2,918,109
|
$63,279,194 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.41%
|
2,903,129
|
$62,997,900 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.38%
|
2,690,124
|
$58,375,691 | — | 31 Dec 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.35%
|
2,490,426
|
$54,044,545 | — | 31 Dec 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.33%
|
2,353,386
|
$51,068,475 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.32%
|
2,312,436
|
$50,179,861 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.32%
|
2,294,506
|
$49,790,780 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.32%
|
2,286,001
|
$49,606,221 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.32%
|
2,281,487
|
$49,508,268 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.31%
|
2,249,867
|
$48,822,113 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.31%
|
2,190,907
|
$47,542,682 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Roivant Sciences Ltd.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Frank Torti | ROIV | Common Shares | Tax liability | -1.17% | -160,035 | 13,576,512 | 31 Mar 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Tax liability | -1.76% | -304,684 | 17,025,890 | 31 Mar 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Tax liability | -0.99% | -187,512 | 18,677,617 | 31 Mar 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Tax liability | -0.31% | -53,826 | 17,330,574 | 30 Mar 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Options Exercise | 0.56% | 97,319 | 17,384,400 | 30 Mar 2026 | Direct | ||
| Matthew Gline | ROIV | Capped Value Appreciation Rights | Options Exercise | -100% | -2,178,150 | 0 | 30 Mar 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Tax liability | -0.16% | -29,809 | 18,865,129 | 30 Mar 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Options Exercise | 0.31% | 58,391 | 18,894,938 | 30 Mar 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Capped Value Appreciation Rights | Options Exercise | -100% | -1,306,889 | 0 | 30 Mar 2026 | Direct | ||
| Meghan FitzGerald | ROIV | Common Shares | Sale | -62% | $1,921,500 | $27.45 | -70,000 | 42,963 | 26 Mar 2026 | Direct |
| Meghan FitzGerald | ROIV | Common Shares | Options Exercise | 162.9% | 70,000 | 112,963 | 26 Mar 2026 | Direct | ||
| Meghan FitzGerald | ROIV | Stock Option (Right to Buy) | Options Exercise | -59% | -70,000 | 48,578 | 26 Mar 2026 | Direct | ||
| Richard Pulik | ROIV | Common Shares | Tax liability | -0.65% | -1,546 | 236,867 | 20 Mar 2026 | Direct | ||
| Jennifer Humes | ROIV | Common Shares | Tax liability | -12.9% | -14,526 | 97,729 | 20 Mar 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Sale | -10.8% | $5,648,000 | $28.24 | -200,000 | 1,647,546 | 17 Mar 2026 | Direct |
| Eric Venker | ROIV | Common Shares | Options Exercise | 12.1% | 200,000 | 1,847,546 | 17 Mar 2026 | Direct | ||
| Eric Venker | ROIV | Stock Option (Right to Buy) | Options Exercise | -3.96% | -200,000 | 4,844,834 | 17 Mar 2026 | Direct | ||
| Melissa B. Epperly | ROIV | Common Shares | Sale | -72.6% | $1,200,573 | $28.68 | -41,861 | 15,804 | 16 Mar 2026 | Direct |
| Frank Torti | ROIV | Common Shares | Sale | -4.1% | $16,159,099 | $27.51 | -587,390 | 13,736,547 | 23 Feb 2026 | Direct |
| Frank Torti | ROIV | Common Shares | Options Exercise | 4.28% | 587,390 | 14,323,937 | 23 Feb 2026 | Direct | ||
| Frank Torti | ROIV | Stock Option (Right to Buy) | Options Exercise | -16.3% | -587,390 | 3,026,184 | 23 Feb 2026 | Direct | ||
| Richard Pulik | ROIV | Common Shares | Tax liability | -0.42% | -1,000 | 238,413 | 20 Feb 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Tax liability | -0.43% | -7,051 | 1,647,546 | 20 Feb 2026 | Direct | ||
| Frank Torti | ROIV | Common Shares | Sale | -6.87% | $27,492,362 | $27.15 | -1,012,610 | 13,736,547 | 20 Feb 2026 | Direct |
| Frank Torti | ROIV | Common Shares | Options Exercise | 7.37% | 1,012,610 | 14,749,157 | 20 Feb 2026 | Direct | ||
| Frank Torti | ROIV | Stock Option (Right to Buy) | Options Exercise | -21.9% | -1,012,610 | 3,613,574 | 20 Feb 2026 | Direct | ||
| Frank Torti | ROIV | Common Shares | Sale | -9.25% | $38,388,000 | $27.42 | -1,400,000 | 13,736,547 | 19 Feb 2026 | Direct |
| Frank Torti | ROIV | Common Shares | Options Exercise | 10.2% | 1,400,000 | 15,136,547 | 19 Feb 2026 | Direct | ||
| Frank Torti | ROIV | Stock Option (Right to Buy) | Options Exercise | -23.2% | -1,400,000 | 4,626,184 | 19 Feb 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Sale | -10.8% | $5,298,000 | $26.49 | -200,000 | 1,654,597 | 13 Feb 2026 | Direct |
| Eric Venker | ROIV | Common Shares | Options Exercise | 12.1% | 200,000 | 1,854,597 | 13 Feb 2026 | Direct | ||
| Eric Venker | ROIV | Stock Option (Right to Buy) | Options Exercise | -3.81% | -200,000 | 5,044,834 | 13 Feb 2026 | Direct | ||
| Keith S. Manchester | ROIV | Common Shares | Sale | -2.42% | $9,956,768 | $26.50 | -375,784 | 15,127,329 | 13 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Daniel Allen Gold | ROIV | Common Shares | Sale | -2.42% | $9,956,768 | $26.50 | -375,784 | 15,127,329 | 13 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| QVT Financial LP | ROIV | Common Shares | Sale | -2.42% | $9,956,768 | $26.50 | -375,784 | 15,127,329 | 13 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Keith S. Manchester | ROIV | Common Shares | Sale | -2.67% | $11,367,000 | $26.75 | -425,000 | 15,503,113 | 12 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Daniel Allen Gold | ROIV | Common Shares | Sale | -2.67% | $11,367,000 | $26.75 | -425,000 | 15,503,113 | 12 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| QVT Financial LP | ROIV | Common Shares | Sale | -2.67% | $11,367,000 | $26.75 | -425,000 | 15,503,113 | 12 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Keith S. Manchester | ROIV | Common Shares | Sale | -2.6% | $11,334,750 | $26.67 | -425,000 | 15,928,113 | 11 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Daniel Allen Gold | ROIV | Common Shares | Sale | -2.6% | $11,334,750 | $26.67 | -425,000 | 15,928,113 | 11 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| QVT Financial LP | ROIV | Common Shares | Sale | -2.6% | $11,334,750 | $26.67 | -425,000 | 15,928,113 | 11 Feb 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Mayukh Sukhatme | ROIV | Common Shares | Other | -1.63% | -312,117 | 18,836,547 | 09 Feb 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Sale | -1.74% | $8,985,003 | $26.47 | -339,441 | 19,148,664 | 09 Feb 2026 | Direct |
| Mayukh Sukhatme | ROIV | Common Shares | Options Exercise | 3.46% | 651,558 | 19,488,105 | 09 Feb 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Stock Option (Right to Buy) | Options Exercise | -100% | -651,558 | 0 | 09 Feb 2026 | Direct | ||
| James C. Momtazee | ROIV | Common Shares | Tax liability | -0.11% | -122 | 109,030 | 20 Jan 2026 | Direct | ||
| James C. Momtazee | ROIV | Common Shares | Award | 0.56% | 609 | 109,152 | 20 Jan 2026 | Direct | ||
| Ilan Oren | ROIV | Common Shares | Tax liability | -0.1% | -124 | 119,428 | 20 Jan 2026 | Direct | ||
| Ilan Oren | ROIV | Common Shares | Award | 0.98% | 1,164 | 119,552 | 20 Jan 2026 | Direct | ||
| Melissa B. Epperly | ROIV | Common Shares | Tax liability | -0.09% | -54 | 57,665 | 20 Jan 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.